A Unique Dermatology Platform Enabling Rapid Development of Next Generation Therapeutics

The problem: existing dermatology therapeutics primarily treat the symptoms of diseases with modest efficacy.

DermBiont’s solution: leverage cutting edge innovation in dermatology and proprietary technology to efficiently develop targeted small molecule therapeutics and novel microbiome-based therapeutics for dermatologic indications that address the root cause of skin diseases.

Our in-house discovery platform for microbiome-based therapeutics is enabled by terabytes of DNA sequencing data derived from human skin samples across healthy individuals and patients with targeted skin diseases. Our cutting-edge proprietary computational biology platform identifies functions that are added to and lost by the microbiome as a result of a multitude of factors, enabling us to uniquely extract insights and understand the implications for skin health.